Phase 4 Heart Disease Trial, Recruiting NCT04769362 Sponsor: Samsung Medical Center Condition: Heart Disease
Back to Heart Disease

Phase 4 Heart Disease Trial, Recruiting

NCT04769362
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are at least 19 years of age.
  • People who have been taking beta-blocker medication continuously for at least 1 year following a heart attack, regardless of when the heart attack was diagnosed.
  • People who are able to verbally confirm they understand the risks and benefits of the trial, and who (or whose legal representative) provide written consent before any study procedures begin.

Who may not be able to join:

  • People whose heart pumping strength (measured by an ultrasound of the heart after a heart attack) was found to be below 40%, or who have never had a heart ultrasound performed after their heart attack.
  • People who have a history of heart failure.
  • People for whom beta-blocker medication is not medically appropriate — for example, those with a history of symptomatic asthma, a serious chronic lung condition, certain heart rhythm problems, a pacemaker, or other reasons a doctor determines make beta-blockers unsuitable.
  • People with a non-heart-related health condition that means life expectancy is less than 1 year, or that may make it difficult to follow the study's requirements, as judged by the trial doctor.
  • People who have a history of atrial fibrillation (an irregular heart rhythm condition).
  • People who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Joo-Yong Hahn, MD,PhD, Samsung Medical Center

Phone: 82-2-3410-6653

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
4 May 2021
Est. completion
31 January 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Major adverse cardiac events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov